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Objective: Patients in the Carotid Revascularization Endarterectomy vs Stenting Trial (CREST) had duplex ultrasound
(DU) scans prior to treatment and during follow-up to document the severity of carotid disease and the anatomic
outcome of carotid endarterectomy (CEA) or carotid artery stenting (CAS). An ultrasound core laboratory (UCL)
reviewed DU data from the clinical sites. This analysis was done to determine the agreement between site-reported and
UCL-veriﬁed DU velocity measurements.
Methods: Clinical site DU worksheets, B-mode images, and Doppler velocity waveforms for the treated carotid arteries
were reviewed at the UCL. The highest internal carotid artery peak systolic velocity (PSV) and associated Doppler angle
were veriﬁed. If the angle was misaligned by >3 degrees, it was remeasured at the UCL and the PSV was recalculated.
Agreement for PSV was deﬁned as site-reported PSV within 65% of UCL-veriﬁed PSV. Transcription errors were
corrected by the UCL but were not considered as disagreements. Follow-up analysis was limited to patients who received
the assigned treatment.
Results: The UCL reviewed 1702 prior-to-treatment and 1743 12-month follow-up DU scans (873 CEA, 870 CAS)
from 111 clinical sites. Site-reported and UCL-veriﬁed PSV agreed in 1124 (66%) of the prior-to-treatment scans and
1200 (69%) of the follow-up scans. In those cases with a disagreement, Doppler angle accounted for disagreement in
339 (59%) of the prior-to-treatment scans and 277 (51%) of the follow-up scans. Based on a threshold PSV for $70%
stenosis of $230 cm/s on the prior-to-treatment scans and $300 cm/s on the follow-up scans, UCL review resulted
in reclassiﬁcation of stenosis severity in 75 (4.4%) of the prior-to-treatment scans and 13 (0.75%) of the follow-up
scans. There is evidence that the proportion of reclassiﬁcation at follow-up was greater for CAS (10 scans; 1.2%) than
for CEA (three scans; 0.34%) (P [ .057).
Conclusions: There was a high rate of agreement between site-reported and UCL-veriﬁed DU results in CREST, and UCL
review was associated with a low rate of stenosis reclassiﬁcation. However, angle alignment errors were quite common and
prompted recalculation of velocity in 20% of prior-to-treatment scans and 18% of follow-up scans. The use of a UCL
provides a uniform process for DU interpretation and can identify sources of error and suggest technical improvements
for future studies. (J Vasc Surg 2014;59:2-7.)The Carotid Revascularization Endarterectomy vs Stent-
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restenosis rates associated with CAS and CEA, differential efﬁ-
cacy of CAS and CEA according to symptomatic status, and
health-related quality of life. A previously reported analysis
found no signiﬁcant difference between CAS and CEA in
the primary end point.2 A separate analysis found similarly
low rates of a composite end point of$70% carotid restenosis
or occlusion within two years after CAS and CEA.3
Patients in CREST had duplex ultrasound (DU) scans
to document the severity of extracranial carotid stenosis
prior to randomization and at speciﬁed intervals following
treatment by CAS or CEA. B-mode ultrasound images
and Doppler velocity waveforms from CREST clinical
sites were forwarded to the University of Washington ultra-
sound core laboratory (UCL) for review and veriﬁcation.
The ﬁnal carotid stenosis classiﬁcation based on the UCL
interpretation of the DU scans was used in the analyses
of CREST data. Although it is common practice to utilize
a core laboratory for clinical trials involving diagnostic
imaging, the role of a core laboratory in this setting has
not been investigated. The purpose of this study was to
evaluate the agreement between the site-reported DU
results and the ﬁnal UCL-veriﬁed stenosis classiﬁcation.
METHODS
Study design and patients. The CREST study design,
eligibility criteria, and randomization procedures have been
reported.1,2,4 The protocol was approved by the ethics
committees of all study institutions and administrative sites.
Written informed consent was obtained from each study
patient (ClinicalTrials.gov number, NCT00004732). Pro-
cedures for review of DU scans performed at CREST
clinical sites by the UCL were approved by the Human
Subjects Division at the University of Washington. Only
the treated carotid sides of patients who underwent their
assigned treatment within 30 days of randomization were
included in this analysis. Although patients in CREST had
DU scans at pretreatment baseline and then at 1, 6, 12, and
24 months after treatment, the DU scans were included in
this analysis if both site-reported and UCL-veriﬁed velocity
data were available at the pretreatment baseline and the
12-month follow-up interval.
Carotid DU. Because there are a variety of methods for
performing and interpreting carotid DU scans, the Univer-
sity of Washington UCL developed a standardized examina-
tion protocol for use in CREST, which was distributed to
the clinical sites. The ultrasound laboratories at CREST clin-
ical sites were then certiﬁed for participation by submitting
ﬁve acceptable carotid DU scans that were done in accor-
dance with the protocol. The UCL protocol required 16
Doppler velocity waveform samples to be taken for each
examination. These included eight samples from each side
of the neck: three from the common carotid artery and three
from the internal carotid artery taken at 1 to 2 cm intervals,
one from the external carotid artery, and one from the verte-
bral artery.5 A constant 60 degree Doppler angle was rec-
ommended for obtaining all velocity waveforms; however,
correctly aligned Doppler angles of less than 60 degreeswere also acceptable. The UCL protocol deﬁned Doppler
angle as the angle between the ultrasound beam and the
long axis of the artery with the Doppler angle cursor set
parallel to the artery wall.
Ultrasound review process. B-mode ultrasound im-
ages and Doppler velocity waveforms were forwarded
from the CREST clinical sites to the University of Wash-
ington UCL along with a worksheet that included the
peak systolic velocity (PSV) from each waveform and the
associated Doppler angle. At the UCL, the clinical site
worksheet data was entered into a database, and a review
form was printed that included the site-reported data.
The UCL review and veriﬁcation process consisted of two
steps: the ﬁrst performed by a sonographer “reader” and
the second by a supervising “reviewer.” The ultrasound
images and velocity waveforms were initially read by
a vascular sonographer certiﬁed by the American Registry
for Diagnostic Medical Sonography who conﬁrmed the
images, velocity values, and angle cursor alignments. The
images and velocity waveforms were then reviewed by
a senior sonographer or the UCL Director. Both reader
and reviewer veriﬁed the selection, location, and labeling of
each B-mode image and waveform pair, and the alignment
of the Doppler angle cursor with the long axis of the artery
on the B-mode image was conﬁrmed. Two different
methods were used in the UCL to measure the Doppler
angle. In the early years of the study, images and wave-
forms were submitted by the clinical sites in hard copy form.
In those cases, lines were drawn on the images aligned with
the long axis of the artery and the Doppler ultrasound
beam, and a handheld protractor was used to measure the
angle. When electronic images became available, the images
were pasted into PowerPoint and an electronic “screen
protractor” (Iconico, Inc, New York, NY) with a resolution
of 0.1 was used to make the measurement.5
If the UCL review process determined that the wave-
form sample used by the site was appropriate to determine
the PSV, the UCL used that sample for veriﬁcation. If
another waveform sample was deemed more appropriate,
then that waveform sample was used by the UCL. For
the waveform sample selected by the UCL, if the angle
was acceptable and correctly aligned, the PSV reported
by the site was deemed veriﬁed and that value was used
for both the site value and the UCL value. If the UCL
review process determined that the Doppler angle was mis-
aligned by >3 degrees, the angle was remeasured, and
the PSV was recalculated, as previously described.5 For
velocity recalculations involving angles of $65 degrees,
the cosine of 65 degrees was used to avoid very high (non-
physiological) calculated velocity values. All other velocity
recalculations used the actual cosine of the new remeasured
angle. The equation for recalculation of the velocity was
ðNew VelocityÞ ¼ ðSite VelocityÞ
 ½cosðSite AngleÞ=cosðNew AngleÞ
The 63 degree range was based on a variability study
performed in the University of Washington Vascular
Table I. Baseline characteristics of the pretreatment patients in Carotid Revascularization Endarterectomy vs Stenting
Trial (CREST)
Baseline characteristics







Mean age 6 SD, years 68.9 6 8.8 69.4 6 8.9 69.0 6 8.9
Female 34.4% 35.9% 34.9%
Symptomatic 52.8% 52.8% 52.8%
Diabetes 30.5% 30.4% 30.5%
Hypertension 85.4% 87.1% 85.9%
Dyslipidemia 84.3% 84.5% 84.4%
Smoke 27.3% 24.0% 26.3%
History of CVD or CABG 44.9% 45.0% 45.0%
Severe stenosis ($70%) 89.8% 78.0%a 86.0%
CABG, Coronary artery bypass graft; CVD, cardiovascular disease; SD, standard deviation; UCL, ultrasound core laboratory.
aP < .001.
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DU images were measured independently by two sonogra-
phers. The 95% conﬁdence limit on the difference between
the two measurements was 3 degrees. Based on this expe-
rience, the 63 degree range has been used in subsequent
studies, and this was applied to the DU protocol used by
the UCL for CREST. If there was disagreement between
the reviewer and reader, the case was returned to the reader
for re-evaluation. If the disagreement was not resolved, the
case was sent to an adjudicator who rendered a ﬁnal deci-
sion and then presented the case to the readers and
reviewers to minimize future interpretation differences.
Corrections and changes marked on the review form
during the reader/reviewer process were entered into the
database. The highest PSV value veriﬁed by the UCL was
used to classify carotid stenosis at pretreatment baseline
and restenosis following CAS or CEA at the 12-month
follow-up interval.3
Deﬁnitions of agreement. The highest PSV reported
by the CREST clinical site was compared with the highest
PSV veriﬁed by the UCL for each baseline and 12-month
follow-up DU scan. Agreement was deﬁned as site-reported
PSV within65% of the UCL-veriﬁed PSV. Most but not all
of the PSV recalculations resulted in disagreements. Some
transcription anddecimal point errorswerediscoveredduring
the review process that involved incorrect transfer of velocity
data from the source B-mode images and Doppler velocity
waveforms to the clinical site worksheets. These errors were
corrected by the UCL prior to further review but were not
considered as disagreements in this analysis.
Velocity thresholds for stenosis and restenosis. For
both the pretreatment baseline and 12-month follow-up
DU scans, PSV thresholds were selected to correspond
to a $70% diameter-reducing lesion. A threshold of
$230 cm/s is commonly used to identify $70% diameter-
reducing stenosis in native extracranial carotid arteries, and
this was applied for the baseline scans.6 Reported experi-
ence indicates that velocities in widely patent carotid stents
are often higher than those in widely patent native carotid
arteries, and use of velocity threshold criteria for stenosis innative carotid arteries could result in overestimation of
restenosis severity in carotid stents.7-11 Based on these
observations, a threshold of $300 cm/s was used to
identify $70% diameter-reducing restenosis after CAS on
the 12-month follow-up scans.3 Since no speciﬁc velocity
thresholds have been established for carotid restenosis after
endarterectomy, the threshold of $300 cm/s was also
used in this analysis on the 12-month follow-up scans after
CEA.
Statistical analysis. Patient and clinical characteristics
of those included and not included in the current study
were performed using c2 and t-tests. Comparisons of
PSV measurements and angle measurements between
CREST clinical sites and the UCL were conducted using
c2 tests.
RESULTS
The University of Washington UCL reviewed 1702
pretreatment baseline and 1743 12-month follow-up DU
scans from 111 CREST clinical sites. The baseline charac-
teristics of the CREST pretreatment patients are listed in
Table I. In addition to the 1702 pretreatment baseline
patients included in this analysis, there were 800 patients
that did not have DU scans reviewed by the UCL. The
only signiﬁcant difference between these two baseline
patient groups with respect to the characteristics listed in
Table I was a higher prevalence of severe carotid stenosis
among patients who had a DU scan reviewed by the
UCL. Of the baseline patients included in this analysis,
approximately one-third were female, just over one-half
had symptomatic carotid artery disease, and carotid stenosis
of $70% diameter-reduction was present in 90%. The
follow-up scans included 873 CEA cases and 870 CAS
cases. Prior to analysis, transcription and decimal point
errors were corrected by the UCL in 30 baseline and 40
follow-up DU scans.
Site-reported and UCL-veriﬁed velocity measurements
agreed in 1124 (66%) of the pretreatment scans and 1200
(69%) of the follow-up scans. There was not a signiﬁcant
difference in the rate of agreement for the CAS and CEA
Fig 1. Clinical site (SITE) maximum peak systolic velocities
(PSVs) on the vertical axis vs ultrasound core laboratory (UCL)-
veriﬁed (CORE LAB) maximum PSVs on the horizontal axis for
the pretreatment baseline duplex scans. Vertical and horizontal
dashed lines mark the velocity threshold of 230 cm/s. The
concentration of data points along the “line of unity” represents
cases where the site PSV value was veriﬁed by the UCL and used as
the UCL value (correct waveform sample and Doppler angle). The
data points forming a line just below the line of unity are an artifact
created by using the cosine of 65 degrees for all PSV recalculations
involving angles of $65 degrees; this was done to avoid very high
(nonphysiological) calculated PSV values.
Fig 2. Clinical site (SITE) maximum peak systolic velocities
(PSVs) on the vertical axis vs ultrasound core laboratory (UCL)-
veriﬁed (CORE LAB) maximum PSV on the horizontal axis for the
12-month follow-up duplex scans. Both carotid stent and carotid
endarterectomy (CEA) cases are included. Vertical and horizontal
dashed lines mark the velocity threshold of 300 cm/s. The
concentration of data points along the “line of unity” represents
exact agreements between the clinical sites and the UCL.
Table II. Agreement between Carotid Revascularization
Endarterectomy vs Stenting Trial (CREST) site-reported
and ultrasound core laboratory (UCL)-veriﬁed peak
systolic velocity (PSV) based on the threshold of 230 cm/s
for $70% stenosis on the pretreatment baseline duplex
scans
UCL-veriﬁed PSV
<230 cm/s $230 cm/s
CREST
Site-reported PSV
<230 cm/s 204 20
$230 cm/s 55 1423
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those cases with a disagreement, Doppler angle accounted
for disagreement in 339 (59%) of the pretreatment and
277 (51%) of the follow-up scans. Angle errors prompted
recalculation of velocity in 346 (20%) of the pretreatment
and 307 (18%) of the follow-up scans. Fig 1 shows the clin-
ical site and UCL-veriﬁed PSV pairs for the pretreatment
baseline scans. The PSV pairs for the 12-month follow-
up scans are shown in Fig 2, including both CAS and
CEA cases.
Based on a threshold PSV of $230 cm/s for $70%
stenosis on the pretreatment scans, UCL review resulted
in reclassiﬁcation of stenosis severity in 75 (4.4%) of the
cases (Table II). These included 20 scans that were reclas-
siﬁed as $70% stenosis and 55 scans that were reclassiﬁed
as <70% stenosis. Using a threshold PSV of $300 cm/s
for $70% stenosis on the follow-up scans, 13 (0.75%) of
the cases were reclassiﬁed by the UCL; eight scans were
reclassiﬁed as $70% stenosis and ﬁve scans were reclassiﬁed
as <70% stenosis. As shown in Table III, the proportion of
reclassiﬁcations at follow-up was greater for CAS (10 scans,
1.2%) than for CEA (three scans, 0.34%) (P ¼ .057). In
Figs 1 and 2, the threshold velocity values for $70%
stenosis are indicated by horizontal and vertical dashed
lines, with reclassiﬁed cases falling in the left upper and
right lower quadrants.
DISCUSSION
The goals of carotid imaging for routine diagnosis are
different from those for clinical trials. When DU is used ina clinical setting, the primary concern is the severity of
carotid disease in an individual patient and the need for
intervention. However, in a multicenter clinical trial, DU
data from many patients at numerous clinical sites must be
combined to support analyses of outcomes and risk factors.
These research applications also often require serial
measurements to document changes in disease severity
over time. Although DU has been used for the evaluation
of carotid artery disease for more than 30 years, speciﬁc
details of testing protocols and interpretation criteria are
known to vary from one laboratory to another.6,12,13 This
variability could be a source of error in clinical trials when
DU is used to identify end points and provide parameters
for analysis. In multicenter clinical trials, a core laboratory
can be used to improve compliance with a standard protocol
to reduce variability. This study examined the role of the
UCL in CREST by determining the rate of agreement and
sources of disagreement between the site-reported and
UCL-veriﬁed DU results.
A comparison of the Doppler velocity measurements
used to classify the severity of carotid stenosis or restenosis
Table III. Agreement between Carotid Revascularization
Endarterectomy vs Stenting Trial (CREST) site-reported
and ultrasound core laboratory (UCL)-veriﬁed peak systolic
velocity (PSV) based on the threshold of 300 cm/s for
$70% stenosis on the 12-month follow-up duplex scans
UCL-veriﬁed PSV
<300 cm/s $300 cm/s
CREST
Site-reported PSV
Total <300 cm/s 1683 8
$300 cm/s 5 47
CAS <300 cm/s 834 5
$300 m/s 5 26
CEA <300 cm/s 849 3
$300 cm/s 0 21
CAS, Carotid artery stent; CEA, carotid endarterectomy.
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UCL-veriﬁed value in almost 70% of the DU scans for both
the native (pretreatment) and follow-up (treated) carotid
arteries. The role of the UCL started with the development
of a standardized DU protocol designed to provide the
data required for the clinical trial, distributing the protocol
to the clinical sites, and certifying the sites by an initial
review of DU scans performed in accordance with the
protocol. The UCL corresponded with the clinical sites
during the certiﬁcation process to resolve protocol issues
and provide feedback. After the trial was underway, the
UCL was available to provide advice and support to the
clinical sites as needed. Comments returned to the sites
served to promote continued adherence to the protocol.
These steps likely resulted in more uniform and consistent
results than would have been obtained if the clinical sites
had been allowed to apply their individual protocols. The
strict two-step reader-reviewer process employed by the
UCL veriﬁed adherence to the prescribed DU protocol,
and the method used for measurement of PSV. Disagree-
ments between reader and reviewer were rare, and a third
review by an adjudicator has been necessary in less than
3% of cases in the University of Washington UCL.5
Incorrect alignment of the Doppler angle cursor was
the most common error identiﬁed and corrected in the
UCL review process. The optimal angle for obtaining
Doppler velocity measurements has been a topic of debate,
with some authorities recommending a constant angle of
60 degrees and others accepting any angle of 60 degrees
or less.6 The process of “angle correction” involves setting
the Doppler angle cursor at the intended angle to the ultra-
sound beam and using the B-mode image to align the
cursor parallel to the arterial wall (the long axis of the
vessel). The instrumentation then uses the set angle and
the Doppler equation to compute a velocity, assuming
that the direction of ﬂow is also parallel to the arterial
wall. These angle corrected velocities increase with
Doppler angle from zero to 90 degrees. If the Doppler
angle is changed from 40 to 60 degrees, the computedDoppler velocity increases by 42% or 2.1% per degree.5
This is a result of hemodynamic factors including helical
ﬂow and turbulence. The UCL protocol for CREST rec-
ommended a constant 60-degree Doppler angle for all
velocity measurements; however, during the review process
angles between 57 and 63 degrees were considered accept-
able since it is unlikely that angle measurements could be
reproduced with greater precision. Correctly measured
and aligned Doppler angles of less than 57 degrees were
also considered acceptable by the UCL. Other sources of
error in determination of PSV at the clinical sites that
were identiﬁed by the UCL included (1) improper place-
ment of the velocity measurement cursor on the Doppler
waveform; (2) not selecting the waveform with the highest
PSV for classiﬁcation of stenosis severity; (3) a waveform
with a correctly aligned angle was identiﬁed by the UCL
and used in place of the waveform selected by the clinical
site that contained an incorrectly aligned angle; and (4)
in the presence of an arrhythmia, an atypical waveform
was selected by the clinical site, but UCL review identiﬁed
a series of waveforms with more normal morphology for
assessment of PSV.
In spite of disagreement between the site-reported and
UCL-veriﬁed velocities in more than 30% of the cases,
when speciﬁc clinically relevant velocity thresholds were
applied to classify carotid stenosis and restenosis, the
UCL review process rarely resulted in reclassiﬁcation of
stenosis severity. This occurred in 4.4% of the pretreatment
baseline scans and 0.75% of the follow-up scans. For the
follow-up scans, reclassiﬁcation was required in 1.2% of
the CAS scans and 0.34% of the CEA scans (P ¼ .057).
This suggests that DU follow-up after CAS may be more
difﬁcult or variable than after CEA. The DU scans per-
formed at pretreatment baseline and one follow-up interval
were selected for this analysis to detect any differences in
agreement between the clinical sites and UCL for native
carotid arteries vs carotid arteries treated by CAS or
CEA. The 12-month follow-up interval was selected to
provide a large number of cases and still allow enough
time for the effects of treatment to become apparent.
Velocity threshold criteria for $70% diameter-reducing
stenosis in native carotid arteries and following treatment
by CAS or CEA were selected for this analysis based on
the clinical relevance of this stenosis severity.3,6 Speciﬁc
DU velocity thresholds for classifying the severity of
stenosis in native carotid arteries are well-established, and
the value of $230 cm/s for $70% stenosis is commonly
used.6,12,14 The CREST threshold of $300 cm/s for
$70% stenosis following treatment has been applied in
a previous report showing a restenosis rate of 5.8% after
both CAS and CEA.3 The present study focused on the
agreement between the site-reported and UCL-veriﬁed
DU velocity measurements, and it did not address correla-
tions between DU and other imaging methods or the
management of recurrent stenosis following endarterec-
tomy or stenting.
The role of the UCL in CREST involved all aspects of
carotid DU scanning, and the results reported by the clinical
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consistency and accuracy. In routine clinical practice where
there may be less emphasis on adherence to a strict protocol
and interpretations are not independently reviewed and veri-
ﬁed, more variability would be expected. However, the DU
results that would have been reported by the clinical sites if
a UCL had not been used in CREST cannot be inferred
from this study. Given the rigorous data requirements and
complexity of multicenter clinical trials, the use of a UCL
is a means to insure consistency and reduce variability. In
conclusion, there was a high rate of agreement between
site-reported and UCL-veriﬁed DU results in CREST.
Incorrect Doppler angle alignment was the most common
source of disagreement. Based on commonly used velocity
threshold criteria for $70% diameter-reducing carotid
stenosis, the standardized protocol and strict review process
provided by the UCL resulted in a low rate of stenosis or
restenosis reclassiﬁcation in CREST.
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